Genetic stability of a Newcastle disease virus vectored infectious laryngotracheitis virus vaccine after serial passages in chicken embryos

Yu, Qingzhong; Li, Yufeng; Dimitrov, Kiril M.; Afonso, Claudio L.; Spatz, Stephen J.; Zsák, László

doi:10.1016/j.vaccine.2019.10.074

Cited by 9 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NDV vector expressing gD of ILTV protected birds against both ILT and ND. Similarly the construct was stable and safe even after 8 chicken egg passages (Yu et al 2020). The F gene of NDV, gD and gI genes of ILTV double recombinant HVT vector vaccine ((HVT-NDV-ILT) showed 97%, 94% and 97% protection against velogenic NDV (GB Texas), ILTV (LT 96-3) and Marek's disease virus (GA 5) strains, respectively (Gergen et al 2019).…”

Section: Vaccinationmentioning

confidence: 95%

Infectious laryngotracheitis: Etiology, epidemiology, pathobiology, and advances in diagnosis and control – a comprehensive review

Gowthaman

Kumar

Koul

et al. 2020

Veterinary Quarterly

View full text Add to dashboard Cite

Infectious laryngotracheitis (ILT) is a highly contagious upper respiratory tract disease of chicken caused by a Gallid herpesvirus 1 (GaHV-1) belonging to the genus Iltovirus, and subfamily Alphaherpesvirinae within Herpesviridae family. The disease is characterized by conjunctivitis, sinusitis, oculo-nasal discharge, respiratory distress, bloody mucus, swollen orbital sinuses, high morbidity, considerable mortality and decreased egg production. It is well established in highly dense poultry producing areas of the world due to characteristic latency and carrier status of the virus. Co-infections with other respiratory pathogens and environmental factors adversely affect the respiratory system and prolong the course of the disease. Latently infected chickens are the primary source of ILT virus (ILTV) outbreaks irrespective of vaccination. Apart from conventional diagnostic methods including isolation and identification of ILTV, serological detection, advanced biotechnological tools such as PCR, quantitative real-time PCR, next generation sequencing, and others are being used in accurate diagnosis and epidemiological studies of ILTV. Vaccination is followed with the use of conventional vaccines including modified live attenuated ILTV vaccines, and advanced recombinant vector vaccines expressing different ILTV glycoproteins, but still these candidates frequently fail to reduce challenge virus shedding. Some herbal components have proved to be beneficial in reducing the severity of the clinical disease. The present review discusses ILT with respect to its current status, virus characteristics, epidemiology, transmission, pathobiology, and advances in diagnosis, vaccination and control strategies to counter this important disease of poultry.

show abstract

Section: Vaccinationmentioning

confidence: 95%

Infectious laryngotracheitis: Etiology, epidemiology, pathobiology, and advances in diagnosis and control – a comprehensive review

Gowthaman

Kumar

Koul

et al. 2020

Veterinary Quarterly

View full text Add to dashboard Cite

show abstract

“…in the same relative position in the NDV genome (). This construct was successfully rescued as expected as multiple studies have demonstrated that recombinant NDVs carrying an insert in this position are viable [30–32].…”

Section: Resultsmentioning

confidence: 88%

“…Moreover, there is no selection pressure for the virus to keep the insert; on the contrary, deletion of the extra sequence may provide a replication advantage to the mutants. While NDV has proved to be a fairly stable platform for the expression of different transgenes [30][31][32], it is an RNA virus with a relatively low-fidelity RDRP [33], and the insert stability is a major concern for all practical applications of NDV vectors.…”

Section: Introductionmentioning

confidence: 99%

Encoding of a transgene in-frame with a Newcastle disease virus protein increases transgene expression and stability

Elbehairy

Samal

2022

Journal of General Virology

View full text Add to dashboard Cite

Newcastle disease virus (NDV) has been extensively explored as a vector for vaccine and oncolytic therapeutic development. In conventional NDV-based vectors, the transgene is arranged as a separate transcription unit in the NDV genome. Here, we expressed haemagglutinin protein (HA) of an avian influenza virus using an NDV vector design in which the transgene ORF is encoded in-frame with the ORF of an NDV gene. This arrangement does not increase the number of transcription units in the NDV genome, and imposes a selection pressure against mutations interrupting the transgene ORF. We placed the HA ORF upstream or downstream of N, M, F and HN ORFs of NDV so that both proteins are encoded in-frame and are separated by either a self-cleaving 2A peptide, furin cleavage site or both. Only constructs in which HA was placed downstream of the NDV HN were viable. These constructs expressed the transgene at a higher level compared to the vector encoding the same transgene in the same position in the NDV genome but as a separate transcription unit. Furthermore, the transgene expressed in one ORF with the NDV protein proved to be more stable over multiple passages. Thus, this design may be useful for applications where the stability of the transgene expression is highly important for a recombinant NDV vector.

show abstract

“…Consecutive passages of recombinant NDVs in eggs do not affect expression of the transgenes. Next-generation sequencing of a recombinant NDV expressing the glycoprotein D (gD) gene of infectious laryngotracheitis virus (ILTV) after eight serial passages in eggs revealed that none of thirteen single-nucleotide polymorphisms were located in the ILTV gD insert or any critical biological domains [ 12 ]. (4) Low risk of gene exchange and recombination.…”

Section: Biological Characteristics Of Ndv As a Vaccine Vectormentioning

confidence: 99%

Newcastle Disease Virus as a Vaccine Vector for 20 Years: A Focus on Maternally Derived Antibody Interference

Cao

et al. 2020

Vaccines

View full text Add to dashboard Cite

It has been 20 years since Newcastle disease virus (NDV) was first used as a vector. The past two decades have witnessed remarkable progress in vaccine generation based on the NDV vector and optimization of the vector. Protective antigens of a variety of pathogens have been expressed in the NDV vector to generate novel vaccines for animals and humans, highlighting a great potential of NDV as a vaccine vector. More importantly, the research work also unveils a major problem restraining the NDV vector vaccines in poultry, i.e., the interference from maternally derived antibody (MDA). Although many efforts have been taken to overcome MDA interference, a lack of understanding of the mechanism of vaccination inhibition by MDA in poultry still hinders vaccine improvement. In this review, we outline the history of NDV as a vaccine vector by highlighting some milestones. The recent advances in the development of NDV-vectored vaccines or therapeutics for animals and humans are discussed. Particularly, we focus on the mechanisms and hypotheses of vaccination inhibition by MDA and the efforts to circumvent MDA interference with the NDV vector vaccines. Perspectives to fill the gap of understanding concerning the mechanism of MDA interference in poultry and to improve the NDV vector vaccines are also proposed.

show abstract

Genetic stability of a Newcastle disease virus vectored infectious laryngotracheitis virus vaccine after serial passages in chicken embryos

Cited by 9 publications

References 33 publications

Infectious laryngotracheitis: Etiology, epidemiology, pathobiology, and advances in diagnosis and control – a comprehensive review

Infectious laryngotracheitis: Etiology, epidemiology, pathobiology, and advances in diagnosis and control – a comprehensive review

Encoding of a transgene in-frame with a Newcastle disease virus protein increases transgene expression and stability

Newcastle Disease Virus as a Vaccine Vector for 20 Years: A Focus on Maternally Derived Antibody Interference

Contact Info

Product

Resources

About